Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference
Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream As…